TOP 10 THINGS EVERY WOMAN SHOULD KNOW ABOUT MENOPAUSE AND HORMONE THERAPY
By Sanaz Majd, MD
The topics of menopause, perimenopause, and hormone replacement therapy have truly gained a lot of headlines in recent years—and for good reason. For decades, millions of women were told to simply tough it out, as both physicians and patients were scared away from using the available hormone treatment options. But the science has evolved dramatically, and so have the options. Whether you’re just starting to notice changes in your cycle, are in the thick of hot flashes and sleepless nights, or are years past your last period and still dealing with symptoms, this article is for you. Here are 10 things every woman should know.
1. Perimenopause and Menopause Are Normal, But Your Symptoms Are Real and Treatable
The transition leading up to menopause is called perimenopause, and it can be a bumpy ride. It typically starts in the mid-40s and brings hormonal shifts that can cause hot flashes, mood swings, trouble sleeping, weight gain, low energy, and brain fog, often in unpredictable waves.
Menopause itself, on the other hand, is simply defined as going 12 consecutive months without a period. The average age in the United States is 51. And if that picture fits, blood tests to “confirm” menopause usually aren’t necessary.
Here’s what many women don’t realize: up to 80% of women experience hot flashes, and they last an average of 7 to 8 years, not just a few months. Vaginal dryness and urinary symptoms (sometimes called genitourinary syndrome of menopause) affect up to half of all women and tend to get worse over time without treatment.
The bottom line: these symptoms are not something you need to just “live with.” Effective treatments exist, and you deserve to know about them.
2. Hormone Therapy Is Still the Most Effective Treatment for Hot Flashes
Despite what you may have heard, hormone therapy (HT) remains the gold standard for treating hot flashes and night sweats. FDA-approved hormone therapy reduces hot flash frequency by about 75% compared to a placebo, hands down the most effective option available. The North American Menopause Society confirmed this in their 2022 position statement (see references below).
3. Timing Matters: There’s a “Window of Opportunity”
One of the biggest takeaways from decades of research is that when you start hormone therapy matters just as much as whether you start it. For women under 60, or within 10 years of their last period, the benefits of hormone therapy generally may outweigh the risks for many. But starting it much later—more than 10 years after menopause or after age 60—is linked to higher risks of heart disease, stroke, blood clots, and dementia.
This concept, known as the “timing hypothesis,” is one of the most important lessons from the landmark Women’s Health Initiative (WHI) studies. The WHI initially scared many women away from hormone therapy, but we now understand that much of that risk applied to older women who started hormones well past menopause, not to women in their 50s experiencing symptoms.
4. Not All Hormone Therapies Are Created Equally
The WHI studied one specific combination: an oral pill made from horse-derived estrogens plus a synthetic progestin. That’s important context, because today there are many different options, including pills, skin patches, gels, sprays, vaginal rings, and more, and the type of hormone and how it’s delivered can make a real difference in both effectiveness and safety.
Think of it this way: saying “hormone therapy” is a bit like saying “blood pressure medication.” There are many varieties, and the right one depends on the individual.
5. Patches and Gels May Be Safer Than Pills for Some Women
When estrogen is delivered through the skin (via a patch, gel, or spray), it goes directly into the bloodstream without passing through the liver first. This matters because it appears to result in a lower risk of blood clots and stroke compared to taking estrogen as a pill.
Skin-based (transdermal) estrogen is especially preferred for women who are overweight, have high triglycerides, or have other risk factors for blood clots. It’s worth noting that these findings come mainly from observational studies rather than the most rigorous type of clinical trial, but the evidence is consistent and widely accepted.
6. Micronized Progesterone May Be a Better Choice Than Older Synthetic Versions
Women who still have a uterus need to take a progesterone-type hormone along with estrogen to protect the uterine lining from endometrial cancer. But not all progesterone is the same.
Micronized progesterone—sometimes called “body-identical” because its chemical structure matches what the body naturally produces—appears to carry lower risks of blood clots, breast cancer, and negative effects on mood and cholesterol compared to older synthetic versions like medroxyprogesterone acetate (the type used in the WHI studies). While these advantages haven’t yet been proven in the largest types of clinical trials, the evidence is encouraging.
Micronized progesterone can be taken every day (which often eliminates periods) or in a cyclical pattern. Your doctor can determine which is best for you.
One important note: FDA-approved bioidentical hormones like these are rigorously tested for safety, effectiveness, and consistency. Compounded “bioidentical” hormones, on the other hand, which are custom-mixed at specialty pharmacies, are not FDA-approved and lack the same quality controls. Most major medical organizations recommend FDA-approved options when they are available.
7. Non-Hormonal Options Are Still Reasonable Options
With that being said, hormonal treatment is not right for everyone. Women who cannot or prefer not to use hormones still have other non-hormonal treatment options, including lifestyle interventions, sleep treatment, therapy, and medications like certain antidepressants (venlafaxine, paroxetine, etc.), oxybutynin, clonidine patch, and gabapentin. (Check out my YouTube video on this topic for an in-depth dive.)
These medications can help, albeit with less efficacy when compared to hormone therapy. But they can certainly help you achieve symptoms that are more tolerable—and reaching 100% resolution of symptoms is not always necessary. These are reasonable alternatives for women who are not good candidates for hormones or prefer not to use them.
8. Exciting New Non-Hormonal Options Have Arrived
For women who can’t or don’t want to use hormones, there’s genuinely good news. A newer class of medications targets the brain’s temperature control center directly.
Fezolinetant was FDA-approved in 2023 and reduces hot flash frequency by roughly 60–80%. A large analysis found it performed comparably to many hormone therapy regimens for reducing hot flashes and outperformed older non-hormonal options. Another similar medication, elinzanetant, has also recently been approved. However, the greatest obstacle currently is insurance coverage and cost, since these are expensive brand-name drugs. If your doctor recommends one of these, it’s worth checking with your insurance plan and asking about manufacturer savings programs.
9. Vaginal and Urinary Symptoms Need Their Own Attention
Vaginal dryness, painful intercourse, and urinary problems are extremely common during and after menopause—and, unlike hot flashes, these symptoms don’t tend to improve on their own. In fact, they usually get worse over time without treatment.
The good news is that effective, low-risk treatments are available. Low-dose vaginal estrogen (available as creams, rings, or tablets) works well and is absorbed minimally into the rest of the body. Because of this minimal absorption, vaginal estrogen is considered safe for a much broader group of women, including many over 60 and those with heart disease risk factors.
As a simple first step, over-the-counter vaginal moisturizers (used regularly, not just during intercourse) have been shown to work as well as prescription options for some symptoms.
10. Treatment Should Be Personalized and There’s No Expiration Date
There is no magic age at which you must stop hormone therapy. The North American Menopause Society is clear on this: hormone therapy can be used for as long as it’s needed to manage symptoms, with regular check-ins with your doctor to reassess the benefits and risks over time.
Every woman’s experience with menopause is different, and treatment should reflect that. The best approach is an ongoing conversation with your physician who can help tailor a plan, whether that includes hormones, non-hormonal options, lifestyle changes, or a combination, to fit your individual needs and health profile. If your primary care doctor isn’t comfortable managing menopause, consider asking for a referral to a menopause specialist. The North American Menopause Society maintains a searchable directory of NAMS-Certified Menopause Practitioners at menopause.org.
The most important thing to take away from all of this? You have options. The science is better than ever, the treatments are safer and more tailored than ever, and no woman should feel like she has to navigate this transition alone or in silence. Talk to your doctor and ask questions because you deserve to feel like yourself again.
REFERENCES
The 2022 Hormone Therapy Position Statement of the North American Menopause Society. Menopause (New York, N.Y.). 2022;29(7):767-794. doi:10.1097/GME.0000000000002028.
The Women’s Health Initiative Randomized Trials and Clinical Practice: A Review. Manson JE, Crandall CJ, Rossouw JE, et al. JAMA. 2024;331(20):1748-1760. doi:10.1001/jama.2024.6542.
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. Flores VA, Pal L, Manson JE. Endocrine Reviews. 2021;42(6):720-752. doi:10.1210/endrev/bnab011.
Opportunity for Improved Menopausal Hormone Therapy Prescribing. Bartz D, Tadikonda A, Manson JE. JAMA. 2026;:2846683. doi:10.1001/jama.2026.1891.
Hormone Therapy for Postmenopausal Women. Pinkerton JV. The New England Journal of Medicine. 2020;382(5):446-455. doi:10.1056/NEJMcp1714787.
Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. El Khoudary SR, Aggarwal B, Beckie TM, et al. Circulation. 2020;142(25):e506-e532. doi:10.1161/CIR.0000000000000912.
Effects of Transdermal Versus Oral Hormone Replacement Therapy in Postmenopause: A Systematic Review. Goldštajn MŠ, Mikuš M, Ferrari FA, et al. Archives of Gynecology and Obstetrics. 2023;307(6):1727-1745. doi:10.1007/s00404-022-06647-5.
HRT Optimization, Using Transdermal Estradiol Plus Micronized Progesterone, a Safer HRT. L’Hermite M. Climacteric : The Journal of the International Menopause Society. 2013;16 Suppl 1:44-53. doi:10.3109/13697137.2013.808563.
Menopausal Hormone Therapy and Breast Cancer: Balancing Risks and Benefits. Bollam R, Karam J, Shufelt C, Faubion SS. Maturitas. 2026;208:108894. doi:10.1016/j.maturitas.2026.108894.
Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause (SKYLIGHT 1): A Phase 3 Randomised Controlled Study. Lederman S, Ottery FD, Cano A, et al. Lancet (London, England). 2023;401(10382):1091-1102. doi:10.1016/S0140-6736(23)00085-5.
